EnteroMedics (ETRM) : The consensus price target for EnteroMedics (ETRM) is $3.75 for the short term with a standard deviation of $4.6. The most optimist securities analyst among the 2 who monitor the stock believes that the stock can reach $7, however, the pessimist price target for the company is $1.
EnteroMedics (ETRM), A increase of 63,458 shares or 10.1% was observed in the short interest of EnteroMedics Inc. The interest on June 30,2016 came in at 691,837 shares and as per the average daily trading of 352,871 shares, the days to cover are 2. The increased interest is 8.6% of the floated shares. The data of June 15,2016 put the interest at 628,379 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.
Also, Roth Capital downgrades its view on EnteroMedics (NASDAQ:ETRM) according to the research report released by the firm to its investors. The shares have now been rated Neutral by the stock experts at the ratings house. Earlier, the shares had a rating of Buy. Roth Capital lowers the price target from $3 per share to $0.5 per share on EnteroMedics . The rating by the firm was issued on June 9, 2016.
EnteroMedics (NASDAQ:ETRM): On Thursdays trading session , Opening price of the stock was $0.44 with an intraday high of $0.4498. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.35. However, the stock managed to close at $0.3572, a loss of 14.71% for the day. On the previous day, the stock had closed at $0.4188. The total traded volume of the day was 4,155,992 shares.
EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Companys neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Companys initial product is the Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limits the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has approvals to commercially launch its product, the Maestro Rechargeable System, in the United States, Australia, the European Economic Area and other countries.